BMJ 2003;326:88-92 ( 11 January )

Clinical review

Skin scarring

A Bayat, specialist registrar in plastic and reconstructive surgery a, D A McGrouther, professor of plastic, reconstructive and hand surgery a, M W J Ferguson, professor b. 

a Department of Plastic and Reconstructive Surgery, South Manchester University Hospital Trust, Wythenshawe Hospital, Wythenshawe, Manchester M23 9LT, b Division of Cells, Immunology and Development, School of Biological Sciences, University of Manchester, 3.239 Stopford Building, Manchester M13 9PT

Correspondence to: A Bayat ardeshir.bayat@man.ac.uk

The first 150 words of the full text of this article appear below.

Deciding whether to treat a scar or leave it alone depends on accurate diagnosis of scar type and scar site, symptoms, severity, and stigma

Each year in the developed world 100 million patients acquire scars, some of which cause considerable problems, as a result of 55 million elective operations and 25 million operations after trauma.1 There are an estimated 11 million keloid scars and four million burn scars, 70% of which occur in children.1 Global figures are unknown but doubtless much higher. People with abnormal skin scarring may face physical, aesthetic, psychological, and social consequences that may be associated with substantial emotional and financial costs. This article reviews the spectrum of abnormal scar types, a range of problems associated with scarring, and provides advice on assessment, treatment, and new therapeutic developments.
Summary points

Skin scars are the normal and inevitable outcome of mammalian tissue repair
Skin scarring covers a wide spectrum of clinical phenotypes from normal fine lines to abnormal widespread, atrophic, hypertrophic, and keloid scars and scar contractures.
Abnormal scars can cause unpleasant symptoms and be aesthetically distressing, disfiguring, and psychosocially and functionally disabling
Appropriate treatment depends on scar type and aetiology. Options vary from leaving alone to using a combination of corticosteroids, surgical excision, and radiotherapy
Recent advances in understanding of the biological basis of embryonic skin healing has led to the development of new drugs to prevent scarring




    Method

This article is based on our scientific and clinical experiences in dermal scarring and on selected articles in recent issues of journals on . . . [Full text of this article]
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Skin scarring: new insights may make adjustment easier
James Partridge and Nichola Rumsey
BMJ 2003 326: 765. [Extract] [Full Text]

Consider stigma due to scars
BMJ 2003 326: 0. [Full Text]

This article has been cited by other articles:

  • Klass, B R, Grobbelaar, A O, Rolfe, K J (2009). Transforming growth factor {beta}1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgrad. Med. J. 85: 9-14 [Abstract] [Full text]  
  • Durani, P., Occleston, N., O'Kane, S., Ferguson, M. W. J. (2008). Avotermin: A Novel Antiscarring Agent. INT J LOW EXTREM WOUNDS 7: 160-168 [Abstract]  
  • Stella, M., Castagnoli, C., Gangemi, E. N. (2008). Postburn Scars: An Update. INT J LOW EXTREM WOUNDS 7: 176-181 [Abstract]  
  • Roques, C., Teot, L. (2007). A Critical Analysis of Measurements Used to Assess and Manage Scars. INT J LOW EXTREM WOUNDS 6: 249-253 [Abstract]  
  • Metcalfe, A. D, Ferguson, M. W.J (2007). Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J R Soc Interface 4: 413-437 [Abstract] [Full text]  
  • Rajkumar, V. S., Shiwen, X., Bostrom, M., Leoni, P., Muddle, J., Ivarsson, M., Gerdin, B., Denton, C. P., Bou-Gharios, G., Black, C. M., Abraham, D. J. (2006). Platelet-Derived Growth Factor-{beta} Receptor Activation Is Essential for Fibroblast and Pericyte Recruitment during Cutaneous Wound Healing. Am. J. Pathol. 169: 2254-2265 [Abstract] [Full text]  
  • Bayat, A., Arscott, G., Ollier, W. E R, Ferguson, M. W J, McGrouther, D A. (2003). 'Aggressive keloid': a severe variant of familial keloid scarring. JRSM 96: 554-555 [Full text]  
  • Partridge, J., Rumsey, N. (2003). Skin scarring: new insights may make adjustment easier. BMJ 326: 765-765 [Full text]  

Rapid Responses:

Read all Rapid Responses

IS BOTULINUM TOXIN [BOTOX] OUR NEXT WEAPON TO COMBAT FACIAL SCARRING?
Y.C. Chan
bmj.com, 13 Jan 2003 [Full text]
Entitlement to scar reduction treatment
Sarah L Davies
bmj.com, 15 Jan 2003 [Full text]
Response to "Skin Scarring" by Bayat , McGrouther and Ferguson
Brian C Sommerlad
bmj.com, 17 Jan 2003 [Full text]
Familial scarring
Nigel P Burrows
bmj.com, 7 Feb 2003 [Full text]
Prevention of Scarring
Sharon J Williams
bmj.com, 5 Jun 2003 [Full text]
Raising the wound pO2 to prevent scarring.
Richard G Fiddian-Green
bmj.com, 6 Jun 2003 [Full text]
The wound gurus did not take the fly.
Richard G Fiddian-Green
bmj.com, 11 Jun 2003 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ